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Abstract: Coenzyme Q10 (CoQ) is a lipid that is ubiquitously synthesized in tissues and has a key
role in mitochondrial oxidative phosphorylation. Its biochemical determination provides insight
into the CoQ status of tissues and may detect CoQ deficiency that can result from either an inherited
primary deficiency of CoQ metabolism or may be secondary to different genetic and environmental
conditions. Rapid identification of CoQ deficiency can also allow potentially beneficial treatment to
be initiated as early as possible. CoQ may be measured in different specimens, including plasma,
blood mononuclear cells, platelets, urine, muscle, and cultured skin fibroblasts. Blood and urinary
CoQ also have good utility for CoQ treatment monitoring.
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1. Introduction
Coenzyme Q10 (CoQ) is a lipid that acts in the mitochondrial respiratory chain (MRC) as the
electron transporter from Enzymatic Complexes I and II to Complex III. Recognized biological functions
of CoQ include an essential role in energy biosynthesis in the form of ATP, free radical detoxification,
stabilization of mitochondrial enzymatic complexes, binding to the permeability transition pore, and
the function of mitochondrial uncoupling proteins [1]. Almost all cells have the capacity for CoQ, and
at least 13 genes have been shown to be required for endogenous production of CoQ. Furthermore,
additional genes also influence CoQ availability such as those related with acetyl-CoA metabolism
or those that can cause secondary reduction in CoQ biosynthesis or increase its degradation [2,3].
CoQ deficiency has been associated with different clinical phenotypes and genetic conditions [4]
and environmental factors can also influence CoQ availability [5]. Regardless of the cause, the
impairment of CoQ status can result in profound deficits to mitochondrial function. Treatment with
CoQ supplementation can result in clinical improvement in CoQ deficiency, and early measurement
of CoQ status is therefore of fundamental importance to allow the rapid initiation of treatment.
Unfortunately, response to CoQ supplementation in trials with other mitochondrial disorders has
been disappointing [6,7]. However, the lack of efficacy could potentially relate to delayed treatment;
consequently, further studies are needed to ascertain whether early identification of CoQ deficiency
in mitochondrial patients may help identify those in whom CoQ supplementation may yet prove
beneficial [7].
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2. Diagnostic Issues of CoQ Deficiency Syndromes
Currently, it is known that 8 of the 13 genes related to CoQ biosynthesis (COQ genes) can
cause human disease [4], but these primary conditions are extremely rare. However, secondary CoQ
deficiency is a common feature in a range of diseases. This susceptibility may be due to the intricate
mechanisms and biological functions in which CoQ participates. Secondary deficiencies can occur
in mitochondrial oxidative phosphorylation (OXPHOS) disorders [2,6,7] and in a broad spectrum of
non-OXPHOS disorders [3]. Interestingly, the prevalence of muscle CoQ deficiency was demonstrated
to be similar for both OXPHOS and non-OXPHOS disease patients [3]. Furthermore, it has been
suggested that CoQ status may be an accurate predictor of deficient activity of MRC components [8,9],
so routine CoQ measurement within the diagnostic workflow of OXPHOS disease seems advisable,
especially for muscle biopsies.
Primary CoQ deficiency is considered a rare mitochondrial disorder associated with a
heterogeneous clinical phenotype [4]. Nevertheless, clinical identification of potential cases is of
paramount importance to initiate investigations that may provide early diagnosis and initiation
of specific treatment, especially as some CoQ-deficient patients respond well to high oral doses of
CoQ [10]. The clinical picture in primary CoQ deficiency can include ataxia with cerebellar involvement
(the most common phenotype of CoQ deficiency syndromes), multiple organ failure in neonatal-onset
forms, kidney disease, deafness, or muscular involvement [4], amongst others. The biochemical
findings consist of a variable degree of CoQ deficiency in tissues (muscle/fibroblasts), which in
turn may cause a reduction in the activity of the CoQ-dependent mitochondrial respiratory chain
(Complexes I + III and Complexes II + III in muscle, Complexes glycerol-3-phosphate (G3P) + III and
Complexes II + III in fibroblasts). However, it is not possible to biochemically distinguish between
primary and secondary CoQ deficiencies nor to identify candidate genes for mutational analysis [11].
The initial stage of laboratory analysis is the biochemical identification of CoQ deficiency. Reduced
activities of CoQ-dependent enzymes are indicative of CoQ deficiency, suggesting a decrease in electron
transfer related to the quinone pool. This is supported by the restoration of Complex II + III activity
after incubation with exogenous ubiquinone [12–14]. Nevertheless, direct quantitative measurement of
CoQ levels is the most reliable test for diagnosis [15]. Essential to this is the choice of tissue for analysis.
This may often be a balance between obtaining the most reliable sample for CoQ measurement and
minimizing invasive procedures. However, some specimens such as plasma may not be suitable for the
diagnosis of primary CoQ deficiency since misleading partial restoration of CoQ values from dietary
sources of CoQ can occur in plasma.
After establishing the biochemical diagnosis, the next step is to identify the specific genetic
defect. Next-generation sequencing has largely replaced the need to serially sequence individual COQ
genes and other genes associated with secondary deficiency and thus has profoundly changed the
diagnostic process [11]. Nevertheless, biochemical measurements still play an important role in the
diagnostic pathway by providing rapid and reliable demonstration of CoQ deficiency that allows early
treatment initiation.
In this chapter, we will review the state of the art in CoQ measurement, utilizing different
biological specimens for the investigation of mitochondrial disorders for both diagnosis and therapeutic
follow-up. Additionally, we will highlight the advantages and pitfalls of CoQ determination in
such specimens.
3. CoQ Determination in Biological Samples. What Can We Expect?
CoQ is ubiquitously synthesized and found in almost all human cells, with higher CoQ
concentrations found in organs with high-energy demand and metabolic rate. The measurement of
both reduced and oxidized forms of CoQ allows for the determination of total CoQ, and this provides
an optimal measure to detect CoQ deficiencies. CoQ levels in a range of specimen types from patients
with mitochondrial diseases have been demonstrated to be lower than control values [6,7,16,17].
However, the particular CoQ distribution in distinct cellular fractions and the complexity of biological
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matrices makes the biological sample choice and preparation a critical step in the CoQ quantification
process [18]. Additionally, since CoQ deficiency may be tissue-specific [19], invasive procedures are
frequently needed in order to assess endogenous CoQ in the target organ, especially in muscle. Thus,
it can be of value to analyze CoQ status in a full range of sample types, as a deficiency may remain
undetected if the appropriate specimen is not chosen. Table 1 summarizes the different biological
specimens and technical approaches for accurate CoQ determination.
Table 1. Advantages and limitations for the CoQ analysis in different biological specimens.
Tissue Advantages Limitations
Plasma
Minimally invasive
Identification of secondary CoQ deficiencies
CoQ treatment monitoring
Low diagnostic yield for CoQ deficiency in
mitochondrial disorders
CoQ values modified by external sources
Leukocytes
Platelets
Minimally invasive
Correlation with CoQ tissue levels
CoQ treatment monitoring
Fresh preparation
Time-consuming
Few reported experiences in
mitochondrial disorders.
Muscle Good diagnostic yield for CoQ deficiencyOther mitochondrial studies can be performed
Invasive
No treatment monitoring
Fibroblasts
Good diagnostic yield for some CoQ deficiencies
Functional studies can be performed (CoQ biosynthesis)
Unlimited biological material for further studies
False negative results in some cases
Urine
Non-invasive
Easily detectable CoQ values
Treatment monitoring purposes
Correlation with kidney CoQ status
remains to be established
Note: Coenzyme Q10 (CoQ).
3.1. Blood Plasma
Plasma CoQ is influenced by both dietary intake and hepatic biosynthesis [20]. Exogenous
CoQ is absorbed through the gut by a complex process that can involve both active and passive
mechanisms [21]. CoQ is then redistributed via the blood linked to cholesterol transporter
lipoproteins [22] that act as the major carrier of CoQ in circulation [23]. The first step of patient
CoQ estimation may be based on plasma measurement. However, CoQ status in plasma can be
affected by both dietary supply and lipoprotein concentration. It is noteworthy that dietary sources
of CoQ can significantly influence plasma CoQ concentrations, contributing up to 25% of the total
amount [23]. For this reason, it has been suggested that plasma CoQ evaluation is not reliable for the
diagnosis of primary CoQ deficiencies [24] as partial correction of CoQ levels may occur due to dietary
consumption of CoQ or increases in cholesterol availability. Indeed, in most patients with primary CoQ
deficiencies, plasma CoQ values are normal. Conversely, a reduction of plasma CoQ is not frequently
observed in the general population, and although there is no demonstrated correlation of plasma and
tissue CoQ values, decreased levels may reliably indicate secondary CoQ deficiencies associated with
diseases such as phenylketonuria and lysosomal storage diseases [25–30]. Whether plasma CoQ can be
used to indicate deficient tissue CoQ status in patients with mitochondrial disorders remains unknown
at present.
While the usefulness of plasma CoQ analysis for the diagnosis of CoQ deficiency remains to be
established, plasma CoQ determination has a critical role for CoQ treatment monitoring [31]. CoQ
therapy is commonly used for the treatment of mitochondrial disorders and the follow-up of these
patients should include regular plasma CoQ quantification. This allows for informed adjustment of
the oral CoQ dose, the control of treatment compliance and confirmation of adequate CoQ intestinal
absorption. The degree of distribution of this supplemented plasma CoQ from blood to affected tissues
remains to be demonstrated and is still a matter of debate.
3.2. Blood Cells
Since analysis of plasma CoQ has limitations for diagnosis and avoidance of invasive first-step
diagnostic procedures for the investigation of mitochondrial patients is desirable, a range of studies
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have tested the reliability of CoQ determination in different blood cell types. Remarkably, leukocyte
CoQ levels correlate well with that of skeletal muscle and therefore represent a good alternative
to evaluate endogenous CoQ [20]. Moreover, these cells can also display changes in cellular CoQ
status upon CoQ supplementation [32]. This approach should be applicable for the identification of
some patients with primary CoQ deficiencies. However, there is a lack of experience with these cells
in most specialist clinical chemistry laboratories. Reference values have been reported [33], but no
large-scale studies of mitochondrial diseases have been published. Unfortunately, the utility of this
specimen currently remains constrained by technical limitations, including difficulties concerning
sample collection and processing.
Similarly, platelet CoQ evaluation seems to be a good indicator of mitochondrial electron transport
chain function [34,35]. Some studies have reported platelets as being a useful material for the
determination of cellular CoQ content and of great utility for clinical monitoring CoQ treatment [36,37].
Although no reference values have been established, it is of note that platelet CoQ measurement may be
advantageous compared to plasma during CoQ supplementation by providing a more representative
measurement of cellular uptake and steady-state conditions [37]. However, even though detailed
information about sample preparation and methods of detection are available, no studies of a large
patient series have been published in relation to platelet CoQ evaluation for diagnosis or for follow-up
in mitochondrial diseases.
Another possibility is to employ lymphoblastoid cell lines [11]. These cells combine the advantages
and disadvantages of mononuclear cells and fibroblasts (see below) in that they do not require invasive
procedures and allow for functional measurements. However, experience with these cells in clinical
laboratories is very limited and the immortalization procedure may cause artifacts. In particular,
immortalized cells tend to compensate the CoQ deficiency by overexpressing components of the CoQ
biosynthetic machinery, so this may mask partial deficiencies.
3.3. Muscle
Muscle biopsy material continues to be the best current option for investigations of CoQ status
in mitochondrial disorders, with a biochemical diagnosis of CoQ deficiency indicated from the
measurement of total CoQ content in muscle homogenates. The main advantage of this biological
specimen is that other biochemical and histological studies may be conducted in parallel to evaluate
the functional condition of the mitochondria, including measurement of mitochondrial respiratory
chain enzyme activities, expression and assembly of mitochondrial complexes, and an assessment
of the characteristic histopathological features of mitochondrial diseases [8]. Typically, a part of the
muscle biopsy is processed in fresh conditions for histopathological and functional studies whilst the
remaining sample is frozen immediately at −80 ◦C until analysis. The frozen samples are useful for
CoQ determination and some other mitochondrial studies, with a minimum of 20–40 mg of muscle
biopsy required for CoQ measurement [8].
Muscle CoQ deficiency is relatively common in patients with mitochondrial disorders [2–8].
Biochemically, it may be concomitantly present with decreased Complexes I + III and Complexes II + III
activities, although other MRC complexes may be affected [8]. However, not all patients with muscle
CoQ deficiency show MRC abnormalities, supporting the role of this molecule in other essential
biological processes beyond energy production [2,17]. Some investigators have proposed CoQ redox
status as a biomarker for oxidative stress [8,38]. However, this requires extensive and complicated
investigations and is unnecessary to establish the diagnosis of CoQ deficiency.
In the last few years, a large list of mutated genes in patients who display secondary muscle
CoQ deficiency has been reported [2–7]. All of these authors concluded that muscle CoQ deficiency
is a frequent finding in mitochondrial disorders in general, with primary CoQ deficiency a much
rarer condition. Clearly, some of these patients may benefit from CoQ supplementation aimed at
restoring CoQ values and thus improving clinical outcomes [39]. Recently, it has been demonstrated
that muscle CoQ values are a good predictor of MRC enzyme function with a utility at least equal to
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citrate synthase activity [9]. This provides added value for muscle CoQ analysis in the investigation of
mitochondrial disorders.
3.4. Fibroblasts
Skin fibroblasts are also a good specimen for demonstrating CoQ deficiency [40]. CoQ content
and MRC enzyme activities can be measured in fibroblasts alongside different in vitro studies for
assessing CoQ synthesis and other metabolic pathways [41,42]. Fibroblast CoQ deficiency may be
accompanied by decreased activities of Complexes G3P + III and Complexes II + III that may or may
not be associated with deficiency of other MRC complexes [17].
Fibroblasts are usually obtained from minimally invasive skin punch biopsies and after culturing
in standard medium (Dulbecco’s Modified Eagle Medium (DMEM) containing 10% Fetal Bovine Serum
(FBS) and 1% penicillin-streptomycin) [40], these cells are amenable to biobank storage, making them
a very valuable material for future investigations. To analyze CoQ content, cultured skin fibroblasts
are homogenized and lipids are extracted before CoQ quantification [43]. In addition, in vitro
investigation of CoQ biosynthetic capacity can be performed in cultured fibroblasts. These assays
are used to analyze the incorporation of radiolabeled substrates into CoQ, such as [3H]-mevalonate
and [14C]-4-hydroxybenzoate, or that of stable isotopes with the measurement of synthesized CoQ by
high pressure liquid chromatography (HPLC) with radiometric or tandem mass spectometry (MS–MS)
detection [41,44,45]. These studies have been demonstrated to be very useful in discriminating between
a primary CoQ deficiency, where the CoQ biosynthesis downstream of the provided substrates is
impaired, and secondary CoQ deficiencies, where other mechanisms leading to CoQ deficiency are
expected [41]. However, some limitations inherent to fibroblasts have been reported. For example,
patients with muscle CoQ deficiency may show normal CoQ values in fibroblasts [46], and secondary
fibroblast CoQ deficiency has been described in patients with other non-mitochondrial diseases [41].
Other investigations in cultured skin fibroblast have provided insights about key
pathophysiological aspects implicated in CoQ deficiency, such as impairment of ATP synthesis or
increased free radical damage [47,48]. Other pathophysiological mechanisms proposed include the
implication of CoQ in pyrimidine biosynthesis (demonstrated in COQ2-mutant fibroblasts) [49]
and the potential induction of mitophagy in response to CoQ deficiency [50]. Cotan et al. [51]
reported that MELAS fibroblasts show a significant reduction of the mitochondrial membrane potential
associated with secondary CoQ deficiency, which triggers mitochondrial degradation by mitophagy.
Fragaki et al. [52] also observed a secondary mitochondrial dysfunction in ganglioside GM3 synthase
(EC:2.4.99.9) deficient patients (including decrease in Complexes I + III and Complexes II + III in
the liver among other MRC abnormalities in fibroblasts), leading to the impairment of normal
mitochondrial electron flow and proton pumping, including a drop in mitochondrial membrane
potential and an increase in apoptosis.
3.5. Urine
Mitochondrial diseases can be associated with renal involvement. Interestingly, primary CoQ
deficiency patients can present with a nephrotic syndrome either in isolation or in combination with
other clinical signs [53,54]. This is perhaps not surprising given that renal tubules and glomerular
podocytes are rich in mitochondria, allowing them to satisfy a high metabolic demand. Moreover,
dramatic clinical improvement of patients with renal disease and CoQ deficiency has been observed
following CoQ supplementation [10]. Urinary tract CoQ analysis could be an appropriate approach
to assessing kidney CoQ status and may help fulfill the critical need for less invasive procedures
to determine tissue CoQ status. Recently, a new methodology for the measurement of CoQ in
urine has been standardized, including the establishment of reference values for a pediatric control
population [55]. This new evaluation of urinary tract CoQ is a noninvasive procedure that might be
useful for estimating CoQ kidney status for diagnosis and especially for CoQ treatment monitoring.
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3.6. Other Biological Samples
CoQ is present in all tissues with its abundance in individual tissues associated with energy
requirements or metabolic activity. Consequently, CoQ content displays a great variability between
different organs and even between cells within the same organ [33]. Several authors have
reported reduced CoQ levels in other tissues such as liver or kidney in patients with mitochondrial
diseases [6,56,57]. However, these procedures require invasive biopsy procedures that can only
be justified if other options for investigations of CoQ status have been exhausted. Experimental
measurement of CoQ has also been reported in cardiac tissue obtained from patients undergoing heart
transplantation [58]. This study found moderate decreases in CoQ in patients with heart failure in
comparison to those without heart failure.
CoQ deficiency can present with profound neurological features, so measurement of CoQ in
cerebrospinal fluid (CSF) has the potential to provide important clinical insight as an indicator of
brain CoQ status. The concentration of CSF CoQ is in the low nanomolar range and therefore requires
specialist analysis by tandem mass spectrometry [59]. Reference ranges have been established for CoQ
in CSF, and a suggested application for this technique is in the identification of cerebral CoQ deficiency,
although pathological samples were not reported [59].
Very recently, a new approach for CoQ determination has been described using non-invasive
mouth swab collection of buccal mucosa cells for CoQ measurement by micro-HPLC. This technique
may prove to be valuable for monitoring pediatric patients [60].
4. CoQ Quantification: Technical Aspects
The gold standard procedure for biochemical diagnosis of CoQ deficiency is the analysis of
CoQ concentration by HPLC with ultraviolet or electrochemical detection [11]. Recently, new
procedures for CoQ determination have been developed based on liquid chromatography-tandem mass
spectrometry [41], allowing not only CoQ quantification but also an estimation of the CoQ biosynthetic
rate in fibroblast cell cultures incubated with adequate CoQ precursors. Methodological approaches
for CoQ measurement are reviewed in another chapter of this issue. Typical CoQ chromatograms from
serum, urine, muscle, and cultured skin fibroblasts are depicted in Figure 1.
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Figure 1. Normal Coenzime Q10 (CoQ) chromatograms of different biological specimens. (A) serum;
(B) urine; (C) muscle; (D) cultured skin fibroblasts. In each specimen, type Q9 and Q10 have a
different retention time that is related to differences in sample matrices and the high-pressure liquid
chromatography (HPLC) column length required for separation.
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5. Conclusions
CoQ is a molecule involved in multiple essential biological functions mainly within the
mitochondria. The intricate metabolic pathways related to CoQ biosynthesis and metabolism underlie
a vulnerability to frequent reductions in the concentration of this molecule as a consequence of different
disease states, but are especially relevant in mitochondrial disorders. Because of this, the measurement
of CoQ status in different biological specimens can be considered an essential part of the diagnostic
and research workflows for patients with mitochondrial disorders and for CoQ treatment monitoring.
This is particularly crucial as CoQ deficiency can be a treatable condition in some cases, so early
recognition of the CoQ-deficient status is important to allow for the commencement of CoQ therapy as
soon as possible.
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